Results 21 to 30 of about 37,664 (239)

Blocking SHP2 benefits FGFR2 inhibitor and overcomes its resistance in FGFR2-amplified gastric cancer [PDF]

eLife
Fibroblast growth factor receptor 2 (FGFR2) is an important member of receptor tyrosine kinase (RTK) family. FGFR2 amplification occurs at a high frequency in gastric cancer (GC) and has been proven to be closely associated with poor prognosis and ...
Yue Zhang, Hanbing Wang, Yutao Wei, Yunfeng Pan, Xueru Song, Jie Shao, Lixia Yu, Tao Shi, Yue Wang   +8 more
doaj   +2 more sources

FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma

Journal of Hepatology, 2021
BACKGROUND AND AIMS About 15% of intrahepatic cholangiocarcinoma (iCCA) express fibroblast growth factor receptor 2 (FGFR2) fusion proteins (FFs), most often in concert with mutational inactivation of TP53, CDKN2A or BAP1.
Giulia Cristinziano, Dante Lamberti, Gian Luca Grazi   +2 more
exaly   +2 more sources

Targeting FGFR2 Positive Gastroesophageal Cancer: Current and Clinical Developments

OncoTargets and Therapy, 2022
Despite recent advances in the systemic treatment of gastroesophageal cancers, prognosis remains poor. Comprehensive molecular analyses have characterized the genomic landscape of gastroesophageal cancer that has established therapeutic targets such as ...
Naureen Starling, Edwina Johnston
exaly   +2 more sources

Clinical Developments and Challenges in Treating FGFR2-Driven Gastric Cancer

Biomedicines
Recent advances in the treatment of gastric cancer (GC) with chemotherapy, immunotherapy, anti-angiogenic therapy and targeted therapies have yielded some improvement in survival outcomes; however, metastatic GC remains a lethal malignancy and amongst ...
John Mariadason, Mariadason John M
exaly   +2 more sources

Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing

Journal of Oncology, 2022
Aberrations in the fibroblast growth factor receptor2 (FGFR2) gene, including genetic alterations and chromosomal rearrangements, lead to the development and progression of cancer with poor prognosis.
S. Hyung, B. Han, Jaeyun Jung, S. Kim, J. Hong, S. Park, D. Zang, Joon-Oh Park, Y. Park, Kyoung-Mee Kim, W. Kang, Jeeyun Lee   +11 more
semanticscholar   +3 more sources

RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations

Cancer Discovery, 2023
Unlike pan-FGFR inhibitors, RLY-4008 was designed to be selective for FGFR2 and induces clinical responses in FGFR2-altered solid tumors without clinically significant FGFR1-mediated hyperphosphatemia and FGFR4-mediated diarrhea.
V. Subbiah, V. Sahai, Dejan Maglic, Kamil Bruderek, B. Touré, Songping Zhao, R. Valverde, Patrick J O'Hearn, D. Moustakas, Heike Schonherr, Nastaran Gerami-Moayed, Alexander M. Taylor, B. M. Hudson, Damian Houde, Debjani Pal, Lindsey Foster, H. Gunaydin, P. Ayaz, Dina A Sharon, L. Goyal, A. Schram, Suneel D. Kamath, C. Sherwin, O. Schmidt-Kittler, K. Jen, F. Ricard, B. Wolf, D. Shaw, D. Bergstrom, J. Watters, Jessica B Casaletto   +30 more
semanticscholar   +1 more source

Landscape of Clinical Resistance Mechanisms to FGFR Inhibitors in FGFR2-Altered Cholangiocarcinoma

Clinical Cancer Research, 2023
Purpose: FGFR inhibitors are effective in FGFR2-altered cholangiocarcinoma, leading to approval of reversible FGFR inhibitors, pemigatinib and infigratinib, and an irreversible inhibitor, futibatinib.
Qibiao Wu, H. Ellis, Giulia Siravegna, Alexa G Michel, B. Norden, F. Fece de la Cruz, E. Balasooriya, Y. Zhen, V. S. Silveira, Jianwei Che, R. Corcoran, N. Bardeesy   +11 more
semanticscholar   +1 more source

Oncogenic activation revealed by FGFR2 genetic alterations in intrahepatic cholangiocarcinomas

Cell & Bioscience, 2023
Background Except for gene fusions, FGFR2 genetic alterations in intrahepatic cholangiocarcinomas (ICCs) have received limited attention, leaving patients harboring activating FGFR2 gene mutations with inadequate access to targeted therapies ...
Xiaohong Pu, Liang Qi, Jia Wu Yan, Zihe Ai, Ping Wu, Fei Yang, Yao Fu, Xing Li, Min Zhang, Beicheng Sun, Shen Yue, Jun Chen   +11 more
doaj   +1 more source

OTUB1 promotes osteoblastic bone formation through stabilizing FGFR2

Signal Transduction and Targeted Therapy, 2023
Bone homeostasis is maintained by the balance between osteoblastic bone formation and osteoclastic bone resorption. Dysregulation of this process leads to multiple diseases, including osteoporosis.
Qiong Zhu, Yesheng Fu, C. Cui, Yiyao Ding, Zhikang Deng, Chao Ning, Fan Hu, Chen Qiu, Biyue Yu, Xu Zhou, Guan Yang, Jiang Peng, Weiguo Zou, C. Liu, Lingqiang Zhang   +14 more
semanticscholar   +1 more source

TNF receptor–related factor 3 inactivation promotes the development of intrahepatic cholangiocarcinoma through NF‐κB‐inducing kinase–mediated hepatocyte transdifferentiation

Hepatology, EarlyView., 2022
Abstract Background and Aims Intrahepatic cholangiocarcinoma (ICC) is a deadly but poorly understood disease, and its treatment options are very limited. The aim of this study was to identify the molecular drivers of ICC and search for therapeutic targets.
Yuto Shiode, Takahiro Kodama, Satoshi Shigeno, Kazuhiro Murai, Satoshi Tanaka, Justin Y. Newberg, Jumpei Kondo, Shogo Kobayashi, Ryoko Yamada, Hayato Hikita, Ryotaro Sakamori, Hiroshi Suemizu, Tomohide Tatsumi, Hidetoshi Eguchi, Nancy A. Jenkins, Neal G. Copeland, Tetsuo Takehara   +16 more
wiley   +1 more source